These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 30229683

  • 1. Banxia Xiexin Decoction Is Effective to Prevent and Control Irinotecan-Induced Delayed Diarrhea in Recurrent Small Cell Lung Cancer.
    Lu H, Qin J, Han N, Xie F, Gong L, Li C.
    Integr Cancer Ther; 2018 Dec; 17(4):1109-1114. PubMed ID: 30229683
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of Shengjiang Xiexin decoction in prophylaxis of chemotherapy-related diarrhea in small cell lung cancer patients: study protocol for a multicenter randomized controlled trial.
    Deng C, Lou Y, Gao Y, Deng B, Su F, Jia L.
    Trials; 2020 May 01; 21(1):370. PubMed ID: 32357899
    [Abstract] [Full Text] [Related]

  • 3. Banxia Xiexin decoction combined with 5-ASA protects against CPT-11-induced intestinal dysfunction in rats via inhibiting TLR4/NF-κB signaling pathway.
    Zou Y, Wang Y, Zhou W, Pei J.
    Immun Inflamm Dis; 2024 Jun 01; 12(6):e1208. PubMed ID: 38860759
    [Abstract] [Full Text] [Related]

  • 4. Identification of the bioactive components of Banxia Xiexin Decoction that protect against CPT-11-induced intestinal toxicity via UPLC-based spectrum-effect relationship analyses.
    Shi JW, Li ZZ, Wu JS, Jin WY, Chang XY, Sun H, Dong L, Jiang ZP, Shi Y.
    J Ethnopharmacol; 2021 Feb 10; 266():113421. PubMed ID: 33022337
    [Abstract] [Full Text] [Related]

  • 5. [Analysis of the Efficacy of Irinotecan in the Second-line Treatment of Refractory and Relapsed Small Cell Lung Cancer].
    Xing H, Zhang J, Ge F, Yu X, Bian H, Zhang F, Fang J.
    Zhongguo Fei Ai Za Zhi; 2021 Mar 20; 24(3):167-172. PubMed ID: 33819966
    [Abstract] [Full Text] [Related]

  • 6. Baicalein, a component of banxia xiexin decoction, alleviates CPT-11-induced gastrointestinal dysfunction by inhibiting ALOX15-mediated ferroptosis.
    Pei J, Zou Y, Zhou W, Wang Y.
    Chem Biol Drug Des; 2023 Dec 20; 102(6):1568-1577. PubMed ID: 37735740
    [Abstract] [Full Text] [Related]

  • 7. [Potential molecular mechanism of Banxia Xiexin Decoction in treatment of colon cancer based on network pharmacology and molecular docking technology].
    Luo YT, Lin LF, Liu YL, Shi GL, Wu YQ, Yang AH, Li H.
    Zhongguo Zhong Yao Za Zhi; 2020 Dec 20; 45(23):5753-5761. PubMed ID: 33496116
    [Abstract] [Full Text] [Related]

  • 8. [Effect of Shengjiang Xiexin Decoction on the Repair of Damaged Rat Intestinal Mucosa after Irinotecan Chemotherapy].
    Wang J, Jia LQ, Tan HY, Pan L, Yu LL, Deng B.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Oct 20; 35(10):1236-43. PubMed ID: 26677677
    [Abstract] [Full Text] [Related]

  • 9. Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer.
    Morise M, Niho S, Umemura S, Matsumoto S, Yoh K, Goto K, Ohmatsu H, Ohe Y.
    Jpn J Clin Oncol; 2014 Sep 20; 44(9):846-51. PubMed ID: 25057092
    [Abstract] [Full Text] [Related]

  • 10. [UPLC/Q-TOF-MS(E) based analysis of chemical composition of banxia xiexin decoction].
    Yan LL, Shi JW, Wang JF, Shi Y.
    Yao Xue Xue Bao; 2013 Apr 20; 48(4):526-31. PubMed ID: 23833940
    [Abstract] [Full Text] [Related]

  • 11. Traditional Chinese medicine Gegen Qinlian decoction ameliorates irinotecan chemotherapy-induced gut toxicity in mice.
    Wu Y, Wang D, Yang X, Fu C, Zou L, Zhang J.
    Biomed Pharmacother; 2019 Jan 20; 109():2252-2261. PubMed ID: 30551482
    [Abstract] [Full Text] [Related]

  • 12. Chinese herbal medicine for irinotecan-induced diarrhea: A systematic review and meta-analysis.
    Lin X, Fang Y, Cheng Y, Wang Q.
    Explore (NY); 2024 Jan 20; 20(2):158-167. PubMed ID: 37640591
    [Abstract] [Full Text] [Related]

  • 13. A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer.
    Alamgeer M, Neil Watkins D, Banakh I, Kumar B, Gough DJ, Markman B, Ganju V.
    Invest New Drugs; 2018 Apr 20; 36(2):288-298. PubMed ID: 29277856
    [Abstract] [Full Text] [Related]

  • 14. Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer.
    Li C, Huang XE, Li Y.
    Asian Pac J Cancer Prev; 2011 Apr 20; 12(2):487-90. PubMed ID: 21545218
    [Abstract] [Full Text] [Related]

  • 15. Uridine diphosphate glucuronide transferase 1A1FNx0128 gene polymorphism and the toxicity of irinotecan in recurrent and refractory small cell lung cancer.
    Yun F, Lulu M, Zhiyu H, Lei G, Haifeng Y, Tao L, Haiyan Y, Conghua X.
    J Cancer Res Ther; 2014 Nov 20; 10 Suppl():C195-200. PubMed ID: 25450281
    [Abstract] [Full Text] [Related]

  • 16. A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer.
    Choudhury NJ, Lai WV, Makhnin A, Heller G, Eng J, Li B, Preeshagul I, Santini FC, Offin M, Ng K, Paik P, Larsen C, Ginsberg MS, Lau Y, Zhang X, Baine MK, Rekhtman N, Rudin CM.
    Clin Cancer Res; 2024 Sep 03; 30(17):3697-3703. PubMed ID: 38940666
    [Abstract] [Full Text] [Related]

  • 17. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Goto K, Ohe Y, Shibata T, Seto T, Takahashi T, Nakagawa K, Tanaka H, Takeda K, Nishio M, Mori K, Satouchi M, Hida T, Yoshimura N, Kozuki T, Imamura F, Kiura K, Okamoto H, Sawa T, Tamura T, JCOG0605 investigators.
    Lancet Oncol; 2016 Aug 03; 17(8):1147-1157. PubMed ID: 27312053
    [Abstract] [Full Text] [Related]

  • 18. A phase I study of amrubicin and fixed dose of irinotecan (CPT-11) in relapsed small cell lung cancer: Japan multinational trial organization LC0303.
    Kawahara M, Kubo A, Komuta K, Fujita Y, Sasaki Y, Fukushima M, Daimon T, Furuse K, Mishima M, Mio T.
    J Thorac Oncol; 2012 Dec 03; 7(12):1845-1849. PubMed ID: 22139390
    [Abstract] [Full Text] [Related]

  • 19. Irinotecan monotherapy as third- or further-line treatment for patients with small cell lung cancer.
    Seto Z, Takata N, Murayama N, Tokui K, Okazawa S, Kambara K, Imanishi S, Miwa T, Hayashi R, Matsui S, Inomata M.
    Tumori; 2021 Dec 03; 107(6):536-541. PubMed ID: 34847814
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review.
    Miyamoto M, Takano M, Kuwahara M, Soyama H, Kato K, Matuura H, Sakamoto T, Takasaki K, Aoyama T, Yoshikawa T, Furuya K.
    Cancer Chemother Pharmacol; 2018 Jan 03; 81(1):111-117. PubMed ID: 29124328
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.